277 related articles for article (PubMed ID: 26912050)
41. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
42. [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].
Hoffmann TK; Whiteside TL; Bier H
HNO; 2005 Mar; 53(3):285-97; quiz 298. PubMed ID: 15759168
[TBL] [Abstract][Full Text] [Related]
43. DNA-based immunotherapy for HPV-associated head and neck cancer.
Aggarwal C
Immunotherapy; 2016 Oct; 8(10):1187-92. PubMed ID: 27605067
[TBL] [Abstract][Full Text] [Related]
44. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
45. Immunity in head and neck cancer.
Schoenfeld JD
Cancer Immunol Res; 2015 Jan; 3(1):12-7. PubMed ID: 25568068
[TBL] [Abstract][Full Text] [Related]
46. Vaccine-based approaches to squamous cell carcinoma of the head and neck.
Zhang X; Moche JA; Farber D; Strome SE
Oral Dis; 2007 Jan; 13(1):17-22. PubMed ID: 17241425
[TBL] [Abstract][Full Text] [Related]
47. [Preclinical models to establish innovative therapy strategies : Ex‑vivo assessment of head and neck tumor chemo- and immune responses].
Wichmann G; Dietz A
HNO; 2016 Jul; 64(7):460-9. PubMed ID: 27259639
[TBL] [Abstract][Full Text] [Related]
48. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions.
Schmitz S; Ang KK; Vermorken J; Haddad R; Suarez C; Wolf GT; Hamoir M; Machiels JP
Cancer Treat Rev; 2014 Apr; 40(3):390-404. PubMed ID: 24176789
[TBL] [Abstract][Full Text] [Related]
49. Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes.
Mellati M; Eaton KD; Brooks-Worrell BM; Hagopian WA; Martins R; Palmer JP; Hirsch IB
Diabetes Care; 2015 Sep; 38(9):e137-8. PubMed ID: 26116720
[No Abstract] [Full Text] [Related]
50. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.
Saba NF; Mody MD; Tan ES; Gill HS; Rinaldo A; Takes RP; Strojan P; Hartl DM; Vermorken JB; Haigentz M; Ferlito A
Crit Rev Oncol Hematol; 2017 Jul; 115():50-58. PubMed ID: 28602169
[TBL] [Abstract][Full Text] [Related]
51. New perspectives in medical approach to therapy of head and neck squamous cell carcinoma.
Santarelli A; Lo Russo L; Bambini F; Campisi G; Lo Muzio L
Minerva Stomatol; 2009 Sep; 58(9):445-52. PubMed ID: 19893469
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy for Esophageal Squamous Cell Carcinoma.
Kojima T; Doi T
Curr Oncol Rep; 2017 May; 19(5):33. PubMed ID: 28361224
[TBL] [Abstract][Full Text] [Related]
53. The fourth modality: immunotherapy for head and neck cancer hits pay dirt.
Bell RB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jun; 121(6):575-7. PubMed ID: 27181440
[No Abstract] [Full Text] [Related]
54. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?
Alorabi M; Shonka NA; Ganti AK
Crit Rev Oncol Hematol; 2016 Mar; 99():170-9. PubMed ID: 26797287
[TBL] [Abstract][Full Text] [Related]
55. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice.
Wang HC; Yeh TJ; Chan LP; Hsu CM; Cho SF
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076306
[TBL] [Abstract][Full Text] [Related]
56. Biology and immunology of cancer stem(-like) cells in head and neck cancer.
Qian X; Ma C; Nie X; Lu J; Lenarz M; Kaufmann AM; Albers AE
Crit Rev Oncol Hematol; 2015 Sep; 95(3):337-45. PubMed ID: 25907739
[TBL] [Abstract][Full Text] [Related]
57. Nasal submucosal administration of antigen-presenting cells induces effective immunological responses in cancer immunotherapy.
Okamoto Y; Fujikawa A; Kurosaki M; Yamasaki K; Sakurai D; Horiguchi S; Nakayama T
Adv Otorhinolaryngol; 2011; 72():149-52. PubMed ID: 21865716
[TBL] [Abstract][Full Text] [Related]
58. Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma.
Almokadem S
Curr Mol Pharmacol; 2016; 9(3):226-230. PubMed ID: 26177644
[TBL] [Abstract][Full Text] [Related]
59. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model.
Gadkaree SK; Fu J; Sen R; Korrer MJ; Allen C; Kim YJ
Head Neck; 2017 Jun; 39(6):1086-1094. PubMed ID: 28323387
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
Moskovitz JM; Moy J; Seiwert TY; Ferris RL
Oncologist; 2017 Jun; 22(6):680-693. PubMed ID: 28507203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
